Argus Investors' Counsel, Inc. Catalent, Inc. Transaction History

Argus Investors' Counsel, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 18, 2023	BUY	$41.39 - $81.0 $11,216 - $21,951	271 Added 2.39%	11,616 $0
Q3 2022 Oct 18, 2022	BUY	$72.36 - $113.1 $8,393 - $13,119	116 Added 1.03%	11,345 $821,000
Q2 2022 Jul 22, 2022	SELL	$87.2 - $114.05 $20,230 - $26,459	-232 Reduced 2.02%	11,229 $1.21 Million
Q1 2022 May 04, 2022	BUY	$94.19 - $124.49 $109,072 - $144,159	1,158 Added 11.24%	11,461 $1.27 Million
Q4 2021 Jan 25, 2022	BUY	$119.57 - $139.07 $112,156 - $130,447	938 Added 10.02%	10,303 $1.32 Million
Q3 2021 Oct 20, 2021	BUY	$109.17 - $142.35 $65,392 - $85,267	599 Added 6.83%	9,365 $1.25 Million
Q2 2021 Jul 30, 2021	BUY	$100.34 - $115.69 $23,178 - $26,724	231 Added 2.71%	8,766 $948,000
Q1 2021 Apr 19, 2021	SELL	$101.51 - $125.27 $25,682 - $31,693	-253 Reduced 2.88%	8,535 $899,000
Q4 2020 Jan 27, 2021	SELL	$85.88 - $105.36 $5,152 - $6,321	-60 Reduced 0.68%	8,788 $915,000
Q3 2020 Oct 30, 2020	BUY	$72.74 - $92.5 $643,603 - $818,440	8,848 New	8,848 $758,000

513

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Argus Investors' Counsel, Inc., based on Form 13F filings with the SEC.

Stay updated on Argus Investors' Counsel, Inc. with notifications on news.